Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Localizing infection with a technetium-99m-labeled peptide: initial results.

C J Palestro1, F L Weiland, J E Seabold

  • 1Division of Nuclear Medicine of Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA. palestro@lij.edu

Nuclear Medicine Communications
|June 14, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A sensitive fluorometric assay for protein-bound DOPA and related products of radical-mediated protein oxidation.

Redox report : communications in free radical research·2016
Same author

Nuclear medicine imaging of bone infections.

Clinical radiology·2016
Same author

Neuroanatomical and functional characterization of CRF neurons of the amygdala using a novel transgenic mouse model.

Neuroscience·2015
Same author

Divergent neuronal circuitries underlying acute orexigenic effects of peripheral or central ghrelin: critical role of brain accessibility.

Journal of neuroendocrinology·2014
Same author

Labeled leukocyte imaging: current status and future directions.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2009
Same author

Imaging of infection and inflammation with 99mTc-Fanolesomab.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2006

A novel peptide imaging agent (99mTc-P483H) safely and effectively detects focal infections, showing accuracy comparable to traditional in vitro-labeled leukocyte imaging. This in vivo method offers a promising alternative for infection detection.

Area of Science:

  • Nuclear Medicine
  • Radiopharmacology
  • Infectious Disease Imaging

Background:

  • In vitro-labeled leukocyte imaging is a standard for infection detection.
  • An in vivo labeling method is highly desirable for improved efficiency and patient care.

Purpose of the Study:

  • To evaluate the safety and efficacy of a leukocyte-avid peptide (P483H) for in vivo infection detection.
  • To determine the impact of peptide dose on imaging performance.
  • To compare the diagnostic accuracy of P483H with in vitro-labeled leukocyte scintigraphy.

Main Methods:

  • A 23-amino acid peptide (P483) was labeled with 99mTc and complexed with heparin (P483H).
  • Thirty patients received varying doses of 99mTc-P483H and were imaged at 15 min and 90-120 min.

Related Experiment Videos

  • Twenty patients also underwent (111)In-labeled leukocyte scintigraphy for comparison.

    • Main Results:

    • The 99mTc-P483H peptide imaging agent was safe, with all adverse events being mild and self-resolving.
    • Sensitivity, specificity, and accuracy for P483H were 0.86, 0.81, and 0.83, respectively, with no improvement from combined early/late imaging.
    • No dose-dependent relationship was observed, and P483H accuracy was identical (0.80) to in vitro-labeled leukocyte imaging in a subset of patients.

    Conclusions:

    • 99mTc-P483H provides a safe, rapid, and accurate method for focal infection detection.
    • The diagnostic performance of 99mTc-P483H is comparable to established in vitro-labeled leukocyte imaging.
    • This in vivo peptide-based imaging agent warrants further clinical investigation.